Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Ghura, Hiba [VerfasserIn]   i
 Keimer, Marin [VerfasserIn]   i
 Au, Anja von [VerfasserIn]   i
 Hackl, Norman J. [VerfasserIn]   i
 Klemis, Verena [VerfasserIn]   i
 Nakchbandi, Inaam [VerfasserIn]   i
Titel:Inhibition of fibronectin accumulation suppresses tumor growth
Verf.angabe:Hiba Ghura, Marin Keimer, Anja von Au, Norman Hackl, Verena Klemis, Inaam A. Nakchbandi
E-Jahr:2021
Jahr:20 July 2021
Umfang:14 S.
Teil:volume:23
 year:2021
 number:9
 pages:837-850
 extent:14
Fussnoten:Gesehen am 07.10.2021
Titel Quelle:Enthalten in: Neoplasia
Ort Quelle:Basingstoke : Stockton Press, 1999
Jahr Quelle:2021
Band/Heft Quelle:23(2021), 9, Seite 837-850
ISSN Quelle:1476-5586
Abstract:Understanding how the extracellular matrix affects cancer development constitutes an emerging research field. Fibronectin and collagen are two intriguing matrix components found in cancer. Large concentrations of fibronectin or collagen type I have been implicated in poor prognosis in patients. In a mouse model, we had shown that genetically decreasing circulating fibronectin resulted in smaller tumors. We therefore aimed to manipulate fibronectin pharmacologically and determine how cancer development is affected. Deletion of fibronectin in human breast cancer cells (MDA-MB-231) using shRNA (knockdown: Kd) improved survival and diminished tumor burden in a model of metastatic lesions and in a model of local growth. Based on these findings, it seemed reasonable to attempt to prevent fibronectin accumulation using a bacterial derived peptide called pUR4. Treatment with this peptide for 10 days in the breast cancer local growth model or for 5 days in a melanoma skin cancer model (B16) was associated with a significant suppression of cancer growth. Treatment aimed at inhibiting collagen type I accumulation without interfering with fibronectin could not affect any changes in vivo . In the absence of fibronectin, diminished cancer progression was due to inhibition of proliferation, even though changes in blood vessels were also detected. Decreased proliferation could be attributed to decreased ERK phosphorylation and diminished YAP expression. In summary, manipulating fibronectin diminishes cancer progression, mostly by suppressing cell proliferation. This suggests that matrix modulation could be used as an adjuvant to conventional therapy as long as a decrease in fibronectin is obtained.
DOI:doi:10.1016/j.neo.2021.06.012
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1016/j.neo.2021.06.012
 Volltext: https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=DOISource&SrcApp=WOS&KeyAID=10.1016%2Fj.neo.2 ...
 DOI: https://doi.org/10.1016/j.neo.2021.06.012
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:activation
 angiogenesis
 apoptosis
 Breast cancer
 Collagen type I
 erk
 Extracellular matrix
 Fibronectin
 Functional upstream domain (FUD)
 ligation
 matrix
 Melanoma
 Pharmacologic matrix modulation
 promotes
 protein
 pUR4
 regulates cell-proliferation
 signaling pathway
K10plus-PPN:1772755117
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68787595   QR-Code
zum Seitenanfang